Physician profile
Poonam Sachdev
NPI 1659529527
$1,000.56
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $244 · 2021: $119 · 2022: $15.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.03 | 2019-2022 | |
| Smith+Nephew, INC. | $119.11 | 2021 | |
| Mylan Specialty L.P. | $107.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $99.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $89.33 | 2019-2020 | |
| Pfizer INC. | $72.90 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $53.31 | 2019 | |
| Glaxosmithkline, LLC. | $44.28 | 2019-2020 | |
| Amgen INC. | $42.84 | 2019-2020 | |
| Sanofi Pasteur INC. | $22.31 | 2019 | |
| Merck Sharp & Dohme LLC | $17.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.88 | 2019 | |
| Lilly USA, LLC | $11.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poonam Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.